Indeed, in mice models, including osteosarcoma and fibrosarcoma [31], prostate cancer [95], RAS-driven lung tumor, breast HER2+ cancer, and also pancreatic cancer xenografts [29], this “citrate strategy” administered orally regressed tumor growth in all cases without remarkable toxicity. The gene discussed is ERBB2; the disease is neoplasm.